Its done consistently to fulfill agendas in endless "articles" but its too ridiculous. Q cannot even be prescribed to women aged 16 to 45. It is restricted to mail order, that alone restricts is potential let alone the safety. Belviq will be readily available to all who need it, with a strong marketing team and budget. Wait until this launches, if a small fraction of the market is prescribed Belviq the cash flow is phenomenal. And way above what Q can ever reach on availability, accessibility and safety issues alone. Belviq is the clear winner with or without Europe. China is a major market for Belviq in the years to come and that's a shoe in for approval.
Sentiment: Strong Buy
Qsymia is being prescribed and taken by women between the ages 16 to 45 today. Thousands of women in this age range took Qsymia this very morning. It's a Arniac myth they can't and it sometimes gets picked up by people writing articles that have agendas and/or the time to do the most basic fact checking before they publish and just write what they read on MBs.
Those poor women!
Can't anyone warn them, or is Qsymia so far below the radar that it's still an unknown compound? That would seem the case judging from prescriptions so far.
Maybe the best thing we can do is make sure that enough of our nation's youth study the doctoral arts of plastic surgery so that the influx of cleft palettes can be handled swiftly.
Sentiment: Hold
that S.A. article was wrong in saying " Q cannot even be prescribed to women aged 16 to 45." that's simply not true,,,,,they are required to have a pregnancy test done first,,,,,,,no different than belviq or most other drugs prescribed to W.O.C.B.A. ,,,,, I ditched VVUS after approval @26.,,,,,, long ARNA until launch,,,,,,they will both fail !!!!!!! good luck to you
If belviq does not surpass total vvus sales in 30 days i will be really surprised !!!
Sentiment: Strong Buy
That would send the pps skyrocketing
Sentiment: Strong Buy